FibroGen, Inc. (NASDAQ:FGEN) Director Buys $87,500.00 in Stock

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck purchased 250,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were purchased at an average price of $0.35 per share, for a total transaction of $87,500.00. Following the completion of the purchase, the director now directly owns 323,722 shares of the company’s stock, valued at approximately $113,302.70. This trade represents a 339.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

FibroGen Stock Down 0.7 %

Shares of FGEN opened at $0.34 on Thursday. The company has a 50-day moving average price of $0.47 and a two-hundred day moving average price of $0.43. The stock has a market cap of $34.32 million, a price-to-earnings ratio of -0.28 and a beta of 0.82. FibroGen, Inc. has a 12 month low of $0.18 and a 12 month high of $2.68.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million. Equities research analysts expect that FibroGen, Inc. will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares during the last quarter. JPMorgan Chase & Co. boosted its position in FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares during the last quarter. FMR LLC boosted its position in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 68,569 shares during the last quarter. Franklin Street Advisors Inc. NC increased its stake in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the period. Finally, Two Sigma Investments LP raised its position in shares of FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 98,888 shares during the last quarter. 72.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on FGEN shares. StockNews.com assumed coverage on FibroGen in a research report on Saturday, March 22nd. They set a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.